Agoraphobia and panic disorder: 3.5 years after alprazolam and/or exposure treatment.
BACKGROUND
Long-term follow-ups after controlled studies of exposure therapy for agoraphobia/panic are few. Most of these studies found that improvement during treatment persists to the end of follow-up.


METHODS
Out of 69 patients with panic disorder plus agoraphobia who had been in an 8-week controlled study of alprazolam and/or exposure, 31 were followed up at a mean of 3.5 years later (4 years after trial entry). The 31 patients followed up included more cases who had relapsed at week 43 than did the group which did not attend the 3.5-year follow-up.


RESULTS
As a group, followed-up cases maintained their gains over the 3.5 years, more so among ex-exposure than ex-relaxation cases. Ex-exposure patients did significantly better than relaxation patients on disability and survival time. Ex-alprazolam and ex-exposure patients did not differ significantly on any variable at the 3.5-year follow-up. No baseline variable predicted outcome at follow-up.


CONCLUSIONS
Present results modestly confirm those of previous studies finding lasting improvement years after exposure, though some residual symptoms were the norm.
Kiliç
C
C
Hacettepe University Faculty of Medicine, Department of Psychiatry, Ankara, Turkey.
Noshirvani
H
H
Başoğlu
M
M
Marks
I
I
D000328:Adult; D000379:Agoraphobia / Q000188:drug therapy*; D000525:Alprazolam / Q000627:therapeutic use*; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D016584:Panic Disorder / Q000188:drug therapy*; D011613:Psychotherapy; D012064:Relaxation Therapy; D016896:Treatment Outcome
D014151:Anti-Anxiety Agents; D000525:Alprazolam